Cytomos raises $5m to scale up cell analysis technology production

The biotech will use the funding to drive sales of its first commercial product

Cytomos has announced that it has raised $5m in an oversubscribed funding round to scale up production of its cell analysis technology.

The Edinburgh-based biotech said it will use the investment to drive sales of its first commercial product, Celledonia, which it said “aims to significantly enhance single-cell analysis”.

Celledonia is built on Cytomos’ cell-analysis technology platform AuraCyt and could, according to the company, “[transform] biological drug discovery, development processes and biologics manufacturing”.

The benchtop cell analyser could help bring new therapies to market up to six months faster and significantly reduce costs by enabling critical decision making earlier, Cytomos outlined, adding that the product’s scalable nature makes it unique in measuring cellular physiology based on intrinsic single-cell properties.

Following the funding round, which was led by existing investors Archangels with participation from Old College Capital, Scottish Enterprise and British Business Bank, Cytomos said it expects to add another four staff to its current 21 employee headcount over the next year as it continues to scale operations.

The company also already has a pipeline of trials planned with global partners.

Cytomos’ Chief Executive Officer, David Rigterink, said: “Successfully raising £5m within a difficult market has been a huge boost for the business. The result is testament to the team’s hard work in delivering our first commercial product with international early adopters.

“Cytomos now has the right building blocks in place to scale quickly, establish a foothold in the US, and continue developing our single-cell analysis technology to support advancements in biological drug development and manufacturing automation.”